BamSEC and AlphaSense Join Forces
Learn More

Esperion Therapeutics Inc. – Material Contracts

NASDAQ: ESPR    
Share price (6/2/26): $3.14    
Market cap (6/2/26): $808 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 20 pages Esperion Therapeutics, Inc. 2022 Stock Option and Incentive Plan
12/34/56
EX-10.3
from 8-K 45 pages Royalty Purchase Agreement Esperion Therapeutics, Inc. as Seller - And - Athyrium Opportunities IV Acquisition LP as Purchaser April 2, 2026
12/34/56
EX-10.27
from 10-K 4 pages Certain Confidential Information, Marked by [***] Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. First Amendment to License and Collaboration Agreement by and Between Esperion Therapeutics, Inc. and Otsuka Pharmaceutical Co., Ltd. November 5, 2025
12/34/56
EX-10.1
from 8-K 13 pages Employment Agreement
12/34/56
EX-10.1
from 8-K 19 pages Esperion Therapeutics, Inc. 2022 Stock Option and Incentive Plan
12/34/56
EX-10.1
from 10-Q 7 pages First Supplemental Indenture Dated as of January 27, 2025 to the Indenture Dated as of December 17, 2024 Between Esperion Therapeutics, Inc., as the Company, and U.S. Bank Trust Company, National Association, as Trustee 5.75% Convertible Senior Subordinated Notes Due 2030
12/34/56
EX-10.1
from 10-Q 60 pages Certain Confidential Information, Marked by [***] Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Royalty Purchase Agreement Esperion Therapeutics, Inc. as Seller - And - Ocm Ip Healthcare Portfolio LP as Purchaser June 27, 2024
12/34/56
EX-10.1
from 8-K 9 pages Transition Agreement
12/34/56
EX-10.2
from 8-K 8 pages Esperion Therapeutics, Inc. 2020 Employee Stock Purchase Plan
12/34/56
EX-10.1
from 8-K 18 pages Esperion Therapeutics, Inc. 2022 Stock Option and Incentive Plan
12/34/56
EX-10.3
from 10-Q 14 pages Certain Confidential Information, Marked by [***] Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. 1st Amendment to the License and Collaboration Agreement by and Between Daiichi Sankyo Company, Limited and Esperion Therapeutics, Inc. January 2, 2024
12/34/56
EX-10.2
from 10-Q 13 pages Certain Confidential Information, Marked by [***] Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. 3rd Amendment to the License and Collaboration Agreement by and Between Daiichi Sankyo Europe Gmbh and Esperion Therapeutics, Inc. January 2, 2024
12/34/56
EX-10.1
from 10-Q 13 pages Certain Confidential Information, Marked by [***] Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Confidential Settlement Agreement and Release
12/34/56
EX-10.1
from 8-K 18 pages Esperion Therapeutics, Inc. 2022 Stock Option and Incentive Plan
12/34/56
EX-10.2
from 8-K 2 pages Holder of Warrants to Purchase Common Stock Issued in December 2021 Re: Amendment to Existing Warrant
12/34/56
EX-10.1
from 8-K 35 pages Securities Purchase Agreement
12/34/56
EX-10.24
from 10-K 7 pages Waiver and Amendment No. 3 to Revenue Interest Purchase Agreement and Amendment No. 2 to Security Agreement
12/34/56
EX-10.1
from 8-K 11 pages Employment Agreement
12/34/56
EX-10.4
from 8-K 11 pages Employment Agreement
12/34/56
EX-10.3
from 8-K 11 pages Employment Agreement
12/34/56